Abstract:Background: Inflammatory bowel disease (IBD) constitutes a group of auto-inflammatory disorders that impact the gastrointestinal tract and other systemic organs. The gut microbiome contributes to IBD pathology through multiple mechanisms. Bacteriophages (hereafter termed phages) are viruses that are able to specifically infect bacteria. Considered as part of the gut microbiome, phages may impact the bacterial community structure in various clinical contexts. Additionally, exogenous phage administration may represent a means of suppressing IBD-associated pathobionts; however, the utilization of phage therapy remains at an early developmental phase. Objectives: Herein, we summarize the latest advances in understanding endogenous phage impacts on the gut microbiome in a healthy gut and in IBD. We highlight the prospect of phage utilization as a targeted mode of pathobiont eradication, for preventing and treating IBD manifestations and complications. Sources: Selected peer-reviewed publications regarding the role of phages in a healthy gut and in IBD, published between 2013 and 2022. Content: The human gut microbiome is increasingly suggested to play a significant role in the onset and progression of multiple non-communicable diseases such as IBD. Several studies suggest that this effect may be mediated by discrete disease-contributing commensals. However, the eradication of such pathogenic bacteria remains a daunting unmet task. Altered community structure in IBD may be influenced by blooms of phages within the gut bacterial ecosystem. Moreover, combinations of phages specifically targeting disease-contributing pathobiont strain clades may be harnessed as potential eradication treatment preventing and treating IBD, while bearing minimal adverse impacts on the surrounding bacterial microbiome. Implications: Understanding the endogenous phage-gut commensal interactions in a healthy gut and in IBD may enable phage utilization in precision gut microbiome editing, towards treating IBD and other non-communicable microbiome-associated diseases. Nevertheless, developing phage combination-mediated IBD pathobiont eradication treatment modalities will likely necessitate better strain-level bacterial target identification and resolution of treatment-related challenges, such as phage delivery, off-target effects, and bacterial resistance.

Inflammation and bacteriophages affect DNA inversion states and functionality of the gut microbiota

Bacteriophages and host inflammation in IBD

A new piece of the microbiota pie: Mining 'omics for DNA inversion states

Prophage induction contributes to alterations in the gut phageome during intestinal inflammation

Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Microbiome-phage interactions in inflammatory bowel disease

Antigenic operon fragmentation and diversification mechanism in Bacteroidota impacts gut metagenomics and pathobionts in Crohn's disease microlesions

Transplantation of bacteriophages from ulcerative colitis patients shifts the gut bacteriome and exacerbates the severity of DSS colitis

Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation

Alteration of the Gut Microbiome in Inflammatory Bowel Disease

Intragenic DNA inversions expand bacterial coding capacity

Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation

Differential translocation of bacteriophages across the intestinal barrier in health and Crohn’s disease

Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease

Disruption of Genes Encoding Putative Zwitterionic Capsular Polysaccharides of Diverse Intestinal Bacteroides Reduces the Induction of Host Anti-Inflammatory Factors

Impact of antibiotic perturbation on fecal viral communities in mice

Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease

Perturbation of the gut microbiome by Prevotella spp. enhances host susceptibility to mucosal inflammation

Plasmids in the human gut reveal neutral dispersal and recombination that is overpowered by inflammatory diseases

Analysis of a phase-variable restriction modification system of the human gut symbiont Bacteroides fragilis